Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 5/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 6/20 | 0.58 |
| ▸ | CDK2 | P24941 | 3/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.58 |
| ▸ | CDK4 | P11802 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | RET | P07949 | 3/20 | 0.54 |
| ▸ | CDK1 | P06493 | 2/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 3/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3251716 | 0.90 | SYK (0.56) | PIK3CGPIK3CAPIK3CBGSK3BCDK2 | |
| SCHEMBL3246779 | 0.86 | CDK1 (0.74) | PIK3CGPIK3CAPIK3CBEGFRGSK3B | |
| SCHEMBL3251689 | 0.84 | CCNB2 (0.51) | PIK3CGPIK3CAPIK3CBGSK3BCDK2 | |
| SCHEMBL3246773 | 0.84 | NUDT1 (0.61) | PIK3CGPIK3CAPIK3CBCDK2CDK4 | |
| SCHEMBL13357453 | 0.83 | CDK1 (0.55) | PIK3CGPIK3CAPIK3CBEGFRGSK3B | |
| SCHEMBL27116598 | 0.81 | PIK3CG (0.83) | PIK3CGPIK3CAPIK3CBEGFRGSK3B | |
| SCHEMBL3243466 | 0.80 | RET (0.54) | PIK3CGPIK3CAPIK3CBGSK3BCDK2 | |
| SCHEMBL3247348 | 0.80 | AURKA (0.58) | GSK3BCDK2DYRK1ACDK4RET | |
| SCHEMBL7993463 | 0.80 | TNNI3K (0.60) | PIK3CGPIK3CAPIK3CBEGFRROCK1 | |
| SCHEMBL12723008 | 0.79 | EGFR (0.59) | PIK3CGPIK3CAPIK3CBEGFRGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | claimed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | claimed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | claimed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | claimed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ERBB2, JAK2, AURKC | PIK3CG 89/4885PIK3CA 67/4885PIK3CB 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.